Indian
Mark Mobius bets on ’50-year rally’ in Indian stocks as China slows down
Mark Mobius “India is on a 50-year rally,” even if there are short...
Installation of electric vehicle charger will cost Delhi residents Rs 2,500
Delhi government is providing a subsidy of Rs 6,000 to the first...
India’s latest Zika outbreak sees surge of nearly 100 cases
"There has been a surge in cases of the Zika virus and the health...
CCI approves acquisition of 100 pc shareholding in Exide Life by HDFC Life Insurance
New Delhi: CCI approves acquisition of 100 pc shareholding in Exide...
International
half of world’s workforce risks losing livelihoods in pandemic: ILO
“It shows I think in the starkest possible terms that the jobs employment crisis and all of its consequences is deepening by comparison with our estimates of 3 weeks ago,” ILO Director-General Guy Ryder told a briefing, foreseeing a “massive” poverty impact.Already, wages of the world’s 2 billion informal workers plunged by an estimated global average of 60% in the first month that the crisis unfolded in each region, the ILO said.
India’s Glenmark to conduct trials for potential COVID-19 drug
Favipiravir, manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp (4901.T) and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.
“After having successfully developed the API and the formulations … Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India,” Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement.
France drafting future insurance backstop for pandemics
A working group set up by French Finance Minister Bruno Le Maire, which includes lawmakers, business lobbies, France’s insurance association and public reinsurer CCR, is examining further insurance options to cover events like pandemics – and aims to put forward proposals by the first half of June, Axa’s Renaud Guidee told Reuters.
Swiss Re swings to 1st-qtr loss as Covid-19 Pandemic bites
Briefs
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Events
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Advertisement
Articles
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Features
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Data
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Interviews
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Facts
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
